Boston Scientific (NYSE:BSX) recently revealed that Xavier Bertrand has been appointed as the new president and Senior Vice President for the EMEA area. During the company’s third-quarter earnings presentation in October, Mike Mahoney, Boston Scientific’s Chairman and CEO, confirmed that Bertrand, previously serving as Vice President of Peripheral Interventions for EMEA, was chosen to spearhead operations in Europe, the Middle East, and Africa. The company has earlier emphasized its dedication to regional development, with special attention to China.
Bertrand took on his new role on December 1, succeeding Eric Thépaut, who retired following a decade of leadership in the EMEA region. In this capacity, Bertrand will oversee the regional business while also joining the global leadership team as an executive committee member at Boston Scientific.
Bertrand brings with him 25 years of expertise in the medtech sector, having led commercial operations in the company’s Peripheral Interventions, Healthcare Partnerships and Solutions, Structural Heart, and Interventional Cardiology divisions. Besides, he has held various roles involving business development and finance across divisions. Starting as a financial analyst for Interventional Cardiology in 2001, Bertrand has accumulated leadership experiences at Medtronic, ATS Medical, and Biosensors. He also once served as the General Manager of Symetis, a structural heart company that Boston Scientific acquired in 2017.
According to Boston Scientific, Bertrand’s extensive experience makes him well-suited to propel further success within the EMEA region. His key strategies include broadening the company’s reach and capitalizing on innovative technologies, while aspiring to cultivate a culture of excellence and inclusivity with his team.
“I am privileged to assume this new responsibility and guide Boston Scientific’s initiatives in the EMEA region, and I am eager to drive sustained, progressive growth with our skilled team,” Xavier Bertrand expressed. “My primary focus will be on broadening access to cutting-edge innovation and minimally-invasive technologies that assist our healthcare partners and enhance patient care.”